🌿 RehabNest, Medication Tracker
rehabnest.rxtoolspro.com | Consistency in medication is consistency in recovery.
💊
Free ToolMedication TrackingMAT Support
Medication Tracker
Whether you're taking medication-assisted treatment (buprenorphine, methadone, naltrexone), psychiatric medication, or other prescriptions, consistent adherence is one of the strongest predictors of recovery success. This tracker helps you log your medications, check off daily doses, monitor your adherence over time, and generate a report to share with your prescriber or treatment team.
✅ Today's Medication Checklist
Check off each medication as you take it. This builds an honest, real-time record of your adherence.
0/0
Add medications to track adherence
💾
Data resets when you close this tab
Your medication list and adherence history are stored in your browser session only. For permanent records, use the print report in the History tab or your pharmacy's app/portal alongside this tool.
💊 Add a Medication
Add each medication you're currently taking, MAT medications, psychiatric medications, or any other prescriptions relevant to your recovery.
My current medications
Keep this list current: Update your medication list whenever your prescriber changes a dose, adds, or removes a medication. An accurate, current list is valuable in emergencies and helps any new provider understand your full treatment picture quickly.
📊 Adherence history
–
Medications tracked
–
Day streak (full adherence)
–
7-day adherence rate
Last 7 days
Sharing with your prescriber or treatment program: Print this page to generate a record of your medication list and recent adherence pattern. Many MAT programs require regular check-ins about adherence, having an organised, honest record supports productive conversations and demonstrates engagement in your treatment.
If you notice gaps in your adherence
Missed doses happen, and the most important response is honesty with your prescriber rather than self-judgment or hiding the gap. Patterns of missed doses often reveal something useful, a time of day that doesn't work, side effects you haven't mentioned, a logistical barrier (pharmacy access, cost), or early signs of ambivalence about treatment that are worth exploring directly. Bring this data to your next appointment rather than waiting to be asked.
📋 Medication-Assisted Treatment (MAT)
MAT is the evidence-based, gold-standard treatment for opioid use disorder and a significant evidence base also supports it for alcohol use disorder. This overview covers the main medications, always follow your prescriber's specific guidance.
💊
Buprenorphine (Suboxone, Subutex, Sublocade)
Opioid Use Disorder
A partial opioid agonist that occupies opioid receptors strongly enough to prevent withdrawal and craving, but with a "ceiling effect" that limits euphoria and respiratory depression risk, making it significantly safer in overdose than full opioid agonists. Often combined with naloxone (in Suboxone) to deter misuse.
Can be prescribed by certified physicians for take-home use, does not require daily clinic visits like methadone
Must begin after withdrawal has started to avoid precipitated withdrawal
Available as sublingual film/tablet (daily) or extended-release injection (Sublocade, monthly)
Significantly reduces overdose mortality compared to no medication treatment
🏥
Methadone
Opioid Use Disorder
A full opioid agonist administered through licensed Opioid Treatment Programs (OTPs), typically requiring daily clinic visits initially. One of the longest-studied and most effective treatments for opioid use disorder, with decades of outcome data supporting its use.
Requires daily dosing at a certified clinic in early treatment, with possible take-home privileges over time
Missing multiple doses reduces tolerance, resuming a previous dose after a gap carries serious overdose risk; always inform your clinic of missed doses
Highly effective at reducing illicit opioid use, overdose, and criminal justice involvement
Some report more involved withdrawal if tapering off, requiring careful, gradual tapering with medical supervision
🛡️
Naltrexone (Vivitrol, ReVia)
Opioid & Alcohol Use Disorder
An opioid antagonist that blocks the effects of opioids entirely (no euphoria possible while on the medication) and also reduces alcohol cravings. Available as a daily oral tablet or a monthly extended-release injection (Vivitrol).
Requires full detoxification (7–10 days opioid-free) before starting, starting too early causes severe precipitated withdrawal
Does not carry abuse potential or sedation, no ceiling effect to manage
The monthly injection (Vivitrol) removes the daily adherence challenge entirely
If opioids are used while on naltrexone, the blockade can wear thin near the end of the dosing interval, this period carries elevated overdose risk if relapse occurs
🍷
Acamprosate & Disulfiram
Alcohol Use Disorder
Acamprosate helps restore the balance of neurotransmitters disrupted by chronic alcohol use, reducing cravings and supporting abstinence maintenance. Disulfiram (Antabuse) creates an unpleasant reaction (nausea, flushing) if alcohol is consumed, functioning as a deterrent rather than a craving-reduction medication.
Acamprosate is typically taken three times daily and works best alongside counselling
Disulfiram requires complete commitment to abstinence and careful patient selection, it does not reduce craving, only deters drinking through aversive reaction
Both are most effective combined with behavioural treatment, not as standalone interventions
Addressing MAT stigma
"Taking medication means I'm not really sober"
This belief, sometimes called "MAT stigma," is widespread but not supported by clinical evidence. Buprenorphine and methadone, taken as prescribed, stabilise brain chemistry without producing the impairment, escalating use, or loss of control that characterises active addiction. Decades of research from SAMHSA, NIDA, and major addiction medicine organisations establish MAT as evidence-based medical treatment, comparable to using insulin for diabetes or antihypertensives for blood pressure. Recovery is defined by your life, relationships, and functioning, not by which evidence-based treatments support that life.
Navigating stigma within 12-step communities
Some 12-step communities historically have not fully embraced MAT, occasionally framing medication use as inconsistent with "true" sobriety. This view is increasingly recognised as outdated and harmful, and many 12-step meetings and members now explicitly welcome people on MAT. If you encounter this stigma, know that it reflects the specific group's culture, not a universal recovery principle, and seek out medication-friendly recovery communities (many exist specifically for this purpose) if needed.
MAT and employment, parenting, and life
People on MAT work, parent, drive, and live full lives, the medications, taken as prescribed, do not impair functioning the way active, uncontrolled substance use does. If you face workplace or legal questions about MAT, the Americans with Disabilities Act provides certain protections, and many resources exist to help navigate these conversations. Your prescriber or treatment program can often provide documentation supporting your treatment status when needed.
Medication adherence and addiction recovery
Medication adherence is among the most studied and most modifiable factors affecting addiction treatment outcomes. For medication-assisted treatment specifically, the relationship between consistent adherence and reduced relapse, reduced overdose, and reduced mortality is one of the strongest and most consistent findings in all of addiction medicine. Despite this evidence, adherence challenges are common, driven by side effects, logistical barriers (cost, pharmacy access, work schedules), stigma, ambivalence about treatment, and simple forgetting in the busy reality of daily life.
A structured tracking system addresses several of these barriers directly. The daily checklist habit creates a routine cue that reduces forgetting. The adherence history makes patterns visible, revealing, for example, that doses are consistently missed on weekends or after certain triggers, which supports targeted problem-solving with your prescriber rather than vague self-criticism. And the printable report makes medication conversations with your healthcare team more efficient and evidence-based, particularly valuable in the time-limited context of most clinical appointments. Use this tracker alongside the appointment tracker to keep your full treatment picture organised.
If cost or access is a barrier to medication adherence: Many MAT medications have patient assistance programs, and Medicaid covers MAT in all states as of federal requirements. SAMHSA's National Helpline (1-800-662-4357) can connect you with low-cost or sliding-scale treatment options. Do not stop or skip medication doses due to cost without first discussing alternatives with your prescriber or program, for some medications, particularly methadone, stopping abruptly carries significant risk.
People also ask about medication tracking in recovery
Medication adherence is one of the strongest predictors of treatment outcomes for medication-assisted treatment such as buprenorphine, methadone, and naltrexone. Research consistently shows that consistent adherence significantly reduces relapse risk, overdose risk, and mortality compared to inconsistent use. Missing doses can trigger withdrawal symptoms or cravings, and inconsistent adherence with certain medications carries safety risks. Tracking adherence helps identify patterns, supports honest conversations with prescribers, and reinforces the daily routine that underpins recovery.
Medication-assisted treatment combines FDA-approved medications with counseling and behavioral therapies to treat substance use disorders, primarily opioid and alcohol use disorder. Common MAT medications include buprenorphine (Suboxone, Subutex), methadone, and naltrexone (Vivitrol) for opioid use disorder, and naltrexone, acamprosate, and disulfiram for alcohol use disorder. MAT is considered the gold-standard, evidence-based treatment for opioid use disorder, significantly reducing mortality and relapse rates compared to non-medication approaches.
No. This is a persistent and harmful misconception. Medications like buprenorphine and methadone work by stabilising brain chemistry, occupying opioid receptors in a controlled way that prevents withdrawal and craving without producing the impairment or escalating use pattern of active addiction. Decades of research from SAMHSA, NIDA, and the American Society of Addiction Medicine establish MAT as evidence-based medical treatment, not a substitute addiction. The stigma around MAT, sometimes present even within recovery communities, is not supported by clinical evidence.